Cytokinetics Launches Myqorzo in Germany
Cytokinetics announced the first commercial European launch of Myqorzo in Germany for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients. "Bringing Myqorzo to Europe marks an exciting new chapter for Cytokinetics as we extend our reach to more patients with symptomatic obstructive hypertrophic cardiomyopathy," said Joseph Dagher, senior VP and head of Europe, Cytokinetics. The availability of Myqorzo in Germany follows European Commission approval in February, which was based on positive results from the pivotal Phase 3 clinical trial SEQUOIA-HCM.
